The way forward for assessing the human health safety of cosmetics in the EU - Workshop proceedings.


Journal

Toxicology
ISSN: 1879-3185
Titre abrégé: Toxicology
Pays: Ireland
ID NLM: 0361055

Informations de publication

Date de publication:
30 04 2020
Historique:
received: 31 01 2020
revised: 21 02 2020
accepted: 25 02 2020
pubmed: 3 3 2020
medline: 1 9 2020
entrez: 3 3 2020
Statut: ppublish

Résumé

Although the need for non-animal alternatives has been well recognised for the human health hazard assessment of chemicals in general, it has become especially pressing for cosmetic ingredients due to the full implementation of testing and marketing bans on animal testing under the European Cosmetics Regulation. This means that for the safety assessment of cosmetics, the necessary safety data for both the ingredients and the finished product can be drawn from validated (or scientifically-valid), so-called "Replacement methods". In view of the challenges for safety assessment without recourse to animal test data, the Methodology Working Group of the Scientific Committee on Consumer Safety organised a workshop in February 2019 to discuss the key issues in regard to the use of animal-free alternative methods for the safety evaluation of cosmetic ingredients. This perspective article summarises the outcomes of this workshop and reflects on the state-of-the-art and possible way forward for the safety assessment of cosmetic ingredients for which no experimental animal data exist. The use and optimisation of "New Approach Methodology" that could be useful tools in the context of the "Next Generation Risk Assessment" and the strategic framework for safety assessment of cosmetics were discussed in depth.

Identifiants

pubmed: 32119890
pii: S0300-483X(20)30060-3
doi: 10.1016/j.tox.2020.152421
pii:
doi:

Substances chimiques

Cosmetics 0

Types de publication

Congress

Langues

eng

Sous-ensembles de citation

IM

Pagination

152421

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Vera Rogiers (V)

Vice-chair of SCCS, Vrije Universiteit Brussel, Brussels, Belgium. Electronic address: SANTE-C2-SCCS@ec.europa.eu.

Emilio Benfenati (E)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.

Ulrike Bernauer (U)

Member of SCCS, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.

Laurent Bodin (L)

Member of SCCS, Alternative Energies and Atomic Energy Commission (CEA), Saclay, France.

Paul Carmichael (P)

Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44, United Kingdom.

Qasim Chaudhry (Q)

Chair of SCCS, University of Chester, Chester, United Kingdom.

Pieter Jan Coenraads (PJ)

Vice-chair of SCCS, University Medical Center Groningen, Groningen, the Netherlands.

Mark T D Cronin (MTD)

Liverpool John Moores University, School of Pharmacy and Biomolecular Sciences, Liverpool, United Kingdom.

Matthew Dent (M)

Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, MK44 Bedfordshire.

Maria Dusinska (M)

Member of SCCS, Norwegian Institute for Air Research (NILU), Kjeller, Norway.

Corie Ellison (C)

The Procter & Gamble Company, Cincinnati, Ohio, USA.

Janine Ezendam (J)

Member of SCCS, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.

Eric Gaffet (E)

Member of SCCS, Institute Jean Lamour (UMR 7198 CNRS Université de Lorraine), Nancy, France.

Corrado Lodovico Galli (CL)

Member of SCCS, Faculty of Pharmaceutical Sciences University of Milan, Milano, Italy.

Carsten Goebel (C)

Coty, Dept of Toxicology, Darmstadt, Germany.

Berit Granum (B)

Member of SCCS, Norwegian Institute of Public Health, Oslo, Norway.

Heli Miriam Hollnagel (HM)

Dow Europe, Toxicology and Environmental Research & Consulting, Horgen, Switzerland.

Petra S Kern (PS)

Procter & Gamble Services NV/SA, Strombeek-Bever, Belgium.

Kirstin Kosemund-Meynen (K)

Coty, Dept of Toxicology, Darmstadt, Germany.

Gladys Ouédraogo (G)

l'Oréal, Research and Development, Paris, France.

Eirini Panteri (E)

Member of SCCS, National and Kapodistrian University of Athens, School of Pharmacy, Division of Pharmaceutical Chemistry, Athens, Greece.

Christophe Rousselle (C)

Member of SCCS, French Agency for Food, Environmental and Occupational Health & Safety (ANSES), Maisons-Alfort, France.

Maciej Stepnik (M)

Member of SCCS, Nofer Institute of Occupational Medicine, Łódź, Poland.

Tamara Vanhaecke (T)

Member of SCCS, Vrije Universiteit Brussel, Brussels, Belgium.

Natalie von Goetz (N)

External expert SCCS, Federal Office of Public Health, Bern, Switzerland.

Andrew Worth (A)

European Commission, Joint Research Centre (JRC), Ispra, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH